Boer R - Search Results

1

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ. Wever EM, et al. Among authors: boer r. J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8. J Natl Cancer Inst. 2010. PMID: 20142584 Free PMC article.

2

Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial.

de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE; ERSPC. de Koning HJ, et al. Among authors: boer r. Int J Cancer. 2002 Mar 10;98(2):268-73. doi: 10.1002/ijc.10188. Int J Cancer. 2002. PMID: 11857418 Clinical Trial.

3

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Draisma G, et al. Among authors: boer r. J Natl Cancer Inst. 2003 Jun 18;95(12):868-78. doi: 10.1093/jnci/95.12.868. J Natl Cancer Inst. 2003. PMID: 12813170 Free article. Clinical Trial.

4

Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation.

Rijnsburger AJ, van Oortmarssen GJ, Boer R, Draisma G, To T, Miller AB, de Koning HJ. Rijnsburger AJ, et al. Among authors: boer r. Int J Cancer. 2004 Jul 10;110(5):756-62. doi: 10.1002/ijc.20143. Int J Cancer. 2004. PMID: 15146566 Clinical Trial.

5

Seventy-five years is an appropriate upper age limit for population-based mammography screening.

Fracheboud J, Groenewoud JH, Boer R, Draisma G, de Bruijn AE, Verbeek AL, de Koning HJ. Fracheboud J, et al. Among authors: boer r. Int J Cancer. 2006 Apr 15;118(8):2020-5. doi: 10.1002/ijc.21560. Int J Cancer. 2006. PMID: 16287064

6

The MISCAN-Fadia continuous tumor growth model for breast cancer.

Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. Tan SY, et al. Among authors: boer r. J Natl Cancer Inst Monogr. 2006;(36):56-65. doi: 10.1093/jncimonographs/lgj009. J Natl Cancer Inst Monogr. 2006. PMID: 17032895

7

Breast cancer screening: evidence for false reassurance?

de Gelder R, van As E, Tilanus-Linthorst MM, Bartels CC, Boer R, Draisma G, de Koning HJ. de Gelder R, et al. Among authors: boer r. Int J Cancer. 2008 Aug 1;123(3):680-6. doi: 10.1002/ijc.23540. Int J Cancer. 2008. PMID: 18484587

8

Mammography screening and risk of breast cancer death: a population-based case-control study.

Otto SJ, Fracheboud J, Verbeek AL, Boer R, Reijerink-Verheij JC, Otten JD, Broeders MJ, de Koning HJ; National Evaluation Team for Breast Cancer Screening. Otto SJ, et al. Among authors: boer r. Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):66-73. doi: 10.1158/1055-9965.EPI-11-0476. Epub 2011 Dec 6. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22147362

9

Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.

de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. de Koning HJ, et al. Among authors: boer r. J Natl Cancer Inst. 1995 Aug 16;87(16):1217-23. doi: 10.1093/jnci/87.16.1217. J Natl Cancer Inst. 1995. PMID: 7563167

10

A longer breast carcinoma screening interval for women age older than 65 years?

Boer R, de Koning HJ, van der Maas PJ. Boer R, et al. Cancer. 1999 Oct 15;86(8):1506-10. doi: 10.1002/(sici)1097-0142(19991015)86:8<1506::aid-cncr17>3.0.co;2-2. Cancer. 1999. PMID: 10526279

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,568 results

Search Page

Filters